Although FGF21-resistance has only been hypothesized in humans, in analogy with the concept of insulin resistance, we could infer that individuals with lower serum FGF21 might be more sensitive to its hepatoprotective action achieving a more pronounced improvement in liver fat accumulation upon a therapeutic intervention. The gene discussed is FGF21; the disease is Insulin resistance.